Compound mutations in BCR::ABL1 contribute to resistance to TKIs in CML patients, which remains a clinical challenge for CML therapy (Cortes et al., 2021). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.